BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 23720945)

  • 1. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E; Louapre C; Lubetzki C; Papeix C
    Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A; Tintoré M
    Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
    Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive multifocal leukoencephalopathy and natalizumab.
    Hellwig K; Gold R
    J Neurol; 2011 Nov; 258(11):1920-8. PubMed ID: 21647730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T; Vennegoor A; Wolbink GJ; Polman CH; Killestein J
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract]   [Full Text] [Related]  

  • 10. Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision.
    Tur C; Tintoré M; Vidal-Jordana A; Castilló J; Galán I; Río J; Arrambide G; Comabella M; Arévalo MJ; Horno R; Vicente MJ; Caminero A; Nos C; Sastre-Garriga J; Montalban X
    Mult Scler; 2012 Aug; 18(8):1193-6. PubMed ID: 22383232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
    J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D
    Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deaths and disability from natalizumab are no longer tolerable: Yes.
    Duquette P
    Mult Scler; 2012 Aug; 18(8):1068-9. PubMed ID: 22807470
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L; Vijiaratnam N; Skibina O
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided).
    Sørensen PS
    Mult Scler; 2012 Aug; 18(8):1070-2. PubMed ID: 22807471
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
    Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting risk of progressive multifocal leukoencephalopathy from natalizumab.
    Ropper AH
    N Engl J Med; 2012 May; 366(20):1938-9. PubMed ID: 22591300
    [No Abstract]   [Full Text] [Related]  

  • 19. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA; van Lierop ZYG; Strijbis EEM; Teunissen CE; Petzold A; Wattjes MP; Barkhof F; de Jong BA; van Kempen ZLE; Killestein J
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33051344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.